Business Standard Supriya Life Sciences bets on regulated markets with new facility
The Mumbai-based pharma company has commissioned a ₹165-crore formulations plant at Ambernath to support contract manufacturing and strengthen its presence in regulated global markets
The Mumbai-based pharma company has commissioned a ₹165-crore formulations plant at Ambernath to support contract manufacturing and strengthen its presence in regulated global markets